Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report report ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...

Alnylam Pharmaceuticals saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare ...